Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/29050| Title: | The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. | Austin Authors: | Foo, Tiffany;Goldstein, David;Segelov, Eva;Shapiro, Jeremy;Pavlakis, Nick;Desai, Jayesh;Yip, Desmond;Zalcberg, John;Price, Timothy J;Nagrial, Adnan;Chantrill, Lorraine;Burge, Matt;Karapetis, Christos S;Tebbutt, Niall C ;Roy, Amitesh C | Affiliation: | Department of Medical Oncology, Wollongong Hospital, Illawarra Shoalhaven Local Health District, Illawarra, NSW, Australia.. Department of Medical Oncology, Prince of Wales Hospital, University of NSW, Sydney, NSW, Australia.. Department of Medical Oncology, School of Clinical Sciences, Monash University and Monash Health, Melbourne, VIC, Australia.. Cabrini Health, Monash University, Melbourne, VIC, Australia.. Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia.. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.. Department of Medical Oncology, Canberra Region Cancer Centre, The Canberra Hospital, Canberra, ACT, Australia.. Alfred Health, Monash University, Melbourne, VIC, Australia.. The Queen Elizabeth Hospital/University of Adelaide, Adelaide, SA, Australia.. Department of Medical Oncology, Westmead and Blacktown Hospitals, University of Sydney, Sydney, NSW, Australia.. Flinders Centre for Innovation in Cancer/Flinders University, Bedford Park, SA, 5042, Australia.. Department of Cancer Care Services, Royal Brisbane Hospital, University of Queensland, Herston, QLD, Australia.. Olivia Newton-John Cancer Wellness and Research Centre |
Issue Date: | Mar-2022 | Date: | 2022-03-15 | Publication information: | Targeted Oncology 2022; 17(2): 95-110 | Abstract: | Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal tract mesenchymal tumours. Tyrosine kinase inhibitors (TKIs) have transformed the management of advanced GIST. Imatinib was the first TKI to gain approval as management for patients with advanced GIST, establishing a new standard of care. Since then, as a result of several trials including the GRID and INVICTUS studies, we now have five lines of approved targeted therapy, including imatinib, sunitinib, regorafenib, ripretinib and avapritinib for the treatment of unresectable, advanced GISTs. In this review, the Australasian Gastrointestinal Trials Group (AGITG) provide an overview of the key trials that have changed clinical practice, discuss the molecular drivers of GISTs, the importance of molecular testing and directing therapy according to molecular targets, as well as future strategies in the management of advanced GISTs. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/29050 | DOI: | 10.1007/s11523-022-00869-y | ORCID: | http://orcid.org/0000-0002-3922-2693 0000-0003-2613-5168 |
Journal: | Targeted oncology | PubMed URL: | 35290591 | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/35290591/ | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.